Skeletal myoblast sheet transplantation improves the diastolic function of a pressure-overloaded right heart

Hoashi, Takaya; Matsumiya, Goro; Miyagawa, Shigeru; Ichikawa, Hajime; Ueno, Takayoshi; Ono, Masamichi; Saito, Atsuhiro; Shimizu, Tatsuya; Okano, Teruo; Kawaguchi, Naomasa; Matsuura, Nariaki; Sawa, Yoshiki

doi:10.1016/j.jtcvs.2009.02.018

Cited by 75 publications

(41 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, when stem/progenitor cells were injected into the myocardium or delivered through bloodstream to the heart, few cells were found engrafted within the host tissue few days after the administration [3][4][5][6][7]. For this reason, a number of biomaterials have been proposed as delivery systems to favor stem/progenitor cells engraftment into the cardiac muscle [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Substrate stiffness affects skeletal myoblast differentiationin vitro

Romanazzo

Forte

Ebara

et al. 2012

Science and Technology of Advanced Materials

View full text Add to dashboard Cite

To maximize the therapeutic efficacy of cardiac muscle constructs produced by stem cells and tissue engineering protocols, suitable scaffolds should be designed to recapitulate all the characteristics of native muscle and mimic the microenvironment encountered by cells in vivo. Moreover, so not to interfere with cardiac contractility, the scaffold should be deformable enough to withstand muscle contraction. Recently, it was suggested that the mechanical properties of scaffolds can interfere with stem/progenitor cell functions, and thus careful consideration is required when choosing polymers for targeted applications. In this study, cross-linked poly-ε-caprolactone membranes having similar chemical composition and controlled stiffness in a supra-physiological range were challenged with two sources of myoblasts to evaluate the suitability of substrates with different stiffness for cell adhesion, proliferation and differentiation. Furthermore, muscle-specific and non-related feeder layers were prepared on stiff surfaces to reveal the contribution of biological and mechanical cues to skeletal muscle progenitor differentiation. We demonstrated that substrate stiffness does affect myogenic differentiation, meaning that softer substrates can promote differentiation and that a muscle-specific feeder layer can improve the degree of maturation in skeletal muscle stem cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Substrate stiffness affects skeletal myoblast differentiationin vitro

Romanazzo

Forte

Ebara

et al. 2012

Science and Technology of Advanced Materials

View full text Add to dashboard Cite

show abstract

“…Initial results from trials in human patients using autologous bone marrow cells have shown that improvement in cardiac function is not satisfactory and remuscularization mediated by donor cells within damaged myocardium is unlikely to be the basis for functional recovery. 7 Recently, emerging tissue engineering approaches, such as synthetic biomaterial cardiac patch, 10 hydrogel, 11,12 or cell sheet, [13][14][15][16][17][18][19][20] offer another pathway to achieve damaged myocardium recovery and may overcome the insufficiency of current treatments. 21 Studies suggest that a three-dimensional (3D) tissue culture environment is necessary for efficient CM survival, functioning myocardial tissue formation in vitro, functional integration, and sustained cardiac recovery.…”

Section: Introductionmentioning

confidence: 99%

“…Recent studies show that cell sheet cardiac graft is relatively easily constructed and also scalable to the human patients. [13][14][15][16][17]19 Combination of proliferative CM and the cell sheet technology, such as layered cell sheet 18 or cell aggregate patch, 20 may enable us to test whether high CM proliferation activity is maintained in a larger-scale engineered cardiac graft. Further studies are necessary to determine whether the high CM proliferation and low CM apoptosis activities within EFCT are purely intrinsic properties of fetal type CMs.…”

mentioning

confidence: 99%

Engineered Fetal Cardiac Graft Preserves Its Cardiomyocyte Proliferation Within Postinfarcted Myocardium and Sustains Cardiac Function

Fujimoto

Clause²,

Liu³

et al. 2011

Tissue Engineering Part A

View full text Add to dashboard Cite

The goal of cellular cardiomyoplasty is to replace damaged myocardium by healthy myocardium achieved by host myocardial regeneration and/or transplantation of donor cardiomyocytes (CMs). In the case of CM transplantation, studies suggest that immature CMs may be the optimal cell type to survive and functionally integrate into damaged myocardium. In the present study, we tested the hypothesis that active proliferation of immature CMs contributes graft survival and functional recovery of recipient myocardium. We constructed engineered cardiac tissue from gestational day 14 rat fetal cardiac cells (EFCT) or day 3 neonatal cardiac cells (ENCT). Culture day 7 EFCTs or ENCTs were implanted onto the postinfarct adult left ventricle (LV). CM proliferation rate of EFCT was significantly higher than that of ENCT at 3 days and 8 weeks after the graft implantation, whereas CM apoptosis rate remained the same in both groups. Echocardiogram showed that ENCT implantation sustained LV contraction, whereas EFCT implantation significantly increased the LV contraction at 8 weeks versus sham group (p < 0.05, analysis of variance). These results suggest that active CM proliferation may play a critical role in immature donor CM survival and the functional recovery of damaged recipient myocardium.

show abstract

“…Two plant extracts improved right ventricular function in rat models of PAH that otherwise produces severe right ventricular failure [24 ,48 ]. A tissue-engineered skeletal myoblast sheet improved right ventricular diastolic function, fibrosis, and capillary density, also in a rat model of PAH [49 ]. Other unique initial studies have suggested a possible therapeutic role for cardiac resynchronization therapy in PAH via right ventricular pacing.…”

Section: Treatment Of Pressure Overloaded Right Ventricular Dysfunctionmentioning

confidence: 94%